SCHEMBL4833530

SCHEMBL4833530

COC(=O)c1ccc(O)cc1NC(=O)C=Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 5/20 0.60
TRPM2 O94759 5/20 0.60
PELI1 Q96FA3 1/20 0.58
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
KDM4E B2RXH2 1/20 0.56
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
MMP1 P03956 3/20 0.55
MMP2 P08253 3/20 0.55
MMP9 P14780 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
HTT P42858 1/20 0.53
MAPT P10636 2/20 0.53
TRPA1 O75762 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833514 1.00 LTB4R (0.60) LTB4RTRPM2PELI1ALDH1A1HPGD
SCHEMBL418157 0.83 ALDH1A1 (0.59) LTB4RTRPM2ALDH1A1HPGDKDM4E
SCHEMBL418156 0.83 ALDH1A1 (0.59) LTB4RTRPM2ALDH1A1HPGDKDM4E
SCHEMBL2274104 0.82 TRPM2 (0.76) LTB4RTRPM2MMP1MMP2MMP9
SCHEMBL2274109 0.82 TRPM2 (0.76) LTB4RTRPM2MMP1MMP2MMP9
SCHEMBL28609663 0.81 SMN1; SMN2 (0.74) LTB4RTRPM2ALDH1A1HPGDKDM4E
SCHEMBL28609662 0.81 SMN1; SMN2 (0.74) LTB4RTRPM2ALDH1A1HPGDKDM4E
SCHEMBL8161855 0.81 LTB4R (0.54) LTB4RTRPM2ALDH1A1HPGDKDM4E
SCHEMBL4825333 0.80 LTB4R (0.48) LTB4RTRPM2ALDH1A1HPGDKDM4E
SCHEMBL4825326 0.80 LTB4R (0.48) LTB4RTRPM2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293790-A1 SUBSTITUTED ARYL OXIMES WYETH (US) 2008-11-27 US disclosed
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US disclosed
EP-1663189-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-07 EP disclosed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 LTB4R 732/4885TRPM2 4568/4885PELI1 2223/4885
US-20080293790-A1 SUBSTITUTED ARYL OXIMES HCCS, AOX1, TET2 LTB4R 1339/4885TRPM2 4793/4885PELI1 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.